Haemonetics Corporation
HAE
$78.71
$3.835.12%
NYSE
| 03/28/2026 | 12/27/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.18% | 3.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.18% | 3.56% | |||
| Cost of Revenue | 8.39% | 2.95% | |||
| Gross Profit | -2.02% | 3.98% | |||
| SG&A Expenses | 18.31% | 5.80% | |||
| Depreciation & Amortization | -4.04% | -2.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.40% | 3.57% | |||
| Operating Income | -32.51% | 3.51% | |||
| Income Before Tax | -147.35% | 16.94% | |||
| Income Tax Expenses | -154.16% | 20.90% | |||
| Earnings from Continuing Operations | -145.03% | 15.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -145.03% | 15.66% | |||
| EBIT | -32.51% | 3.51% | |||
| EBITDA | -29.73% | 1.59% | |||
| EPS Basic | -145.59% | 17.62% | |||
| Normalized Basic EPS | -40.03% | 5.34% | |||
| EPS Diluted | -145.97% | 17.28% | |||
| Normalized Diluted EPS | -39.78% | 5.08% | |||
| Average Basic Shares Outstanding | -1.21% | -1.68% | |||
| Average Diluted Shares Outstanding | -1.62% | -1.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||